SuperworthMirum Pharmaceuticals EPS MIRM
Diluted earnings per share by quarter and over the last twelve months, from 2018.
- Last 12 months, to Jun 30, 2026
- −$14.55
- Latest quarter, Q2 FY26
- −$1.06
- Fiscal year 2025
- −$0.48
Mirum Pharmaceuticals' earnings per share was −$14.55 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$1.06.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.48 | n/a |
| FY2024 | −$1.85 | n/a |
| FY2023 | −$4.08 | n/a |
| FY2022 | −$4.02 | n/a |
| FY2021 | −$2.80 | n/a |
| FY2020 | −$4.08 | n/a |
| FY2019 | −$9.31 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$1.06 | n/a | −$14.55 | |
| Q1 FY26 | −$13.43 | n/a | −$13.61 | |
| Q4 FY25 | −$0.11 | n/a | −$0.48 | |
| Q3 FY25 | $0.05 | n/a | −$0.86 | |
| Q2 FY25 | −$0.12 | n/a | −$1.21 | |
| Q1 FY25 | −$0.30 | n/a | −$1.61 | |
| Q4 FY24 | −$0.49 | n/a | −$1.85 | |
| Q3 FY24 | −$0.30 | n/a | −$2.13 | |
| Q2 FY24 | −$0.52 | n/a | −$2.40 | |
| Q1 FY24 | −$0.54 | n/a | −$3.82 | |
| Q4 FY23 | −$0.77 | n/a | −$4.08 | |
| Q3 FY23 | −$0.57 | n/a | −$4.30 |
Against its peers
Companies in Drug Manufacturers - General nearest Mirum Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| MIRMMirum Pharmaceuticals | −$14.55 | |
| KNSAKiniksa Pharmaceuticals International | $0.97 | +2325% a year |
| LGNDLigand Pharmaceuticals | $9.40 | |
| AMRXAmneal Pharmaceuticals | $0.49 | +4800% a year |
| INDVIndivior Pharmaceuticals | $2.78 | +227% a year |
| ARQTArcutis Biotherapeutics | $0.22 | |
| LQDALiquidia | $1.39 | |
| ALKSAlkermes plc. | $0.38 | −82% a year |
| OGNOrganon | $0.77 | −71% a year |
| TGTXTG Therapeutics | $2.74 | +641% a year |
| PTGXProtagonist Therapeutics | $1.03 | +47% a year |
| Peer median | $1.00 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Mirum Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.